$1.43
+0.03 (+2.14%)
Open$1.41
Previous Close$1.40
Day High$1.45
Day Low$1.39
52W High$3.90
52W Low$1.22
Volume—
Avg Volume55.6K
Market Cap71.37M
P/E Ratio—
EPS$-0.22
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+1,893.0% upside
Current
$1.43
$1.43
Target
$28.50
$28.50
$17.57
$28.50 avg
$41.49
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 405.7K | 11.04M | 11.56M |
| Net Income | -11,952,165 | -536,425 | -578,623 |
| Profit Margin | -2,928.8% | -4.9% | -5.0% |
| EBITDA | -13,213,375 | -810,707 | -735,622 |
| Free Cash Flow | — | -370,627 | -351,629 |
| Rev Growth | — | +9.7% | -0.5% |
| Debt/Equity | — | 0.96 | 0.89 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |